Rock Ventures Iii, L.P.Thir... Net Worth

The estimated Net Worth of Rock Ventures Iii, L.P.Thir... is at least 43.2 百万$ dollars as of 12 November 2021. Rock Thir owns over 1,900,000 units of Nurix Therapeutics stock worth over 27,306,501$ and over the last 4 years Rock sold NRIX stock worth over 15,922,000$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Rock Thir NRIX stock SEC Form 4 insiders trading

Rock has made over 1 trades of the Nurix Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently Rock sold 1,900,000 units of NRIX stock worth 15,922,000$ on 12 November 2021.

The largest trade Rock's ever made was selling 1,900,000 units of Nurix Therapeutics stock on 12 November 2021 worth over 15,922,000$. On average, Rock trades about 380,000 units every 0 days since 2020. As of 12 November 2021 Rock still owns at least 1,148,780 units of Nurix Therapeutics stock.

You can see the complete history of Rock Thir stock trades at the bottom of the page.

Insiders trading at Nurix Therapeutics

Over the last 4 years, insiders at Nurix Therapeutics have traded over 1,236,800$ worth of Nurix Therapeutics stock. The most active insiders traders include Group, Llc Green Jeremy Red...、Clay B Siegall、Biomedical Innovation Maste.... On average, Nurix Therapeutics executives and independent directors trade stock every 15 days with the average trade being worth of 116,806$. The most recent stock trade was executed by Christine Ring on 3 September 2024, trading 9,050 units of NRIX stock currently worth 42,173$.

What does Nurix Therapeutics do?

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.

Complete history of Rock Thir stock trades at Jounce Therapeutics Inc、Revolution Medicines Inc、Nurix Therapeutics

Nurix Therapeutics executives and stock owners

Nurix Therapeutics executives and other stock owners filed with the SEC include:

• Dr. Arthur T. Sands M.D., Ph.D.,
  CEO, Pres & Director
• Dr. Arthur T. Sands,
  CEO, Pres & Director
• Dr. Gwenn M. Hansen Ph.D.,
  Chief Scientific Officer
• Dr. Christine Ring,
  Gen. Counsel & Sec.
• Stefani A. Wolff,
  COO & Exec. VP of Product Devel.
• Dr. Michael Rapé Ph.D.,
  Founder & Member of Scientific Advisory Board
• Rita Kwong,
  Sr. Accounting Mang.
• Howard A. Simon J.D., Esq., SPHR,
  VP of Operations & Corp. Counsel
• Johannes Van Houte,
  Chief Financial Officer
• Prof. Arthur Weiss,
  Founder & Member of Scientific Advisory Board
• Dr. Michael Rapé Ph.D.,
  Founder & Member of Scientific Advisory Board
• Dr. John Kuriyan,
  Founder & Member of Scientific Advisory Board
• Rock Ventures Iii, L.P.Thir...,
  
• Gwenn Hansen,
  Chief Scientific Officer
• Leon Chen,
  Director
• Lori Anne Kunkel,
  Director
• David L. Lacey,
  Director
• Julia P Gregory,
  Director
• Jeffrey K Tong,
  Director
• Group L Pcolumn Group Gp, L...,
  
• Group L P Svennilson Peter ...,
  
• Robert Tjian,
  Director
• Group, Llc Green Jeremy Red...,
  
• Biomedical Innovation Maste...,
  10% owner
• Arthur T Sands,
  President, CEO
• Stefani Wolff,
  EVP and COO
• Rock Ventures Iii, L.P.Thir...,
  
• Houte Hans Van,
  Chief Financial Officer
• Pierre Beaurang,
  Chief Business Officer
• Clay B Siegall,
  Director
• Paul M Silva,
  Director
• Judith A Reinsdorf,
  Director
• Edward C Saltzman,
  Director
• Christine Ring,
  Chief Legal Officer